Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Latest filing published 09 Dec 2025 for Akero Therapeutics, Inc.. Read the official filing
Filing timeline
BuySaleScott A. Gangloff
Insider track record
Disclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Scott A. Gangloff: trading record in brief
Scott A. Gangloff (senior executive) discloses dealings in Akero Therapeutics, Inc. to SEC (Form 4). Between 16 December 2024 and 9 December 2025, the trades on record add up to 6 filings.
The open-market record consists of 1 sale worth €41k, with no purchase. Outside the open market, there are 2 share grants and 1 option exercise. So far in 2025, the count stands at no purchases and 1 sale.
The record was last updated on 9 December 2025 with a transaction in Akero Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Scott A. Gangloff
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
5,088 sharesCommon StockSEC:0001193125-25-312111:0
21,263 sharesCommon StockSEC:0001193125-25-312111:1
2,600 shares@ US$19.62100.0% of flowCommon StockSEC:0000950170-25-110352:0
299 shares@ US$23.8686.7% of flowCommon StockSEC:0000950170-25-093317:0
848 shares@ US$54.8448.1% of flowCommon StockSEC:0000950170-25-088640:0
24,300 shares0Common StockSEC:0000950170-24-138138:0
6 of 6 declarations
